Evidence map›Paper›PMID 39788945›Full record

ArticleCell death & disease2025

Enhancing immunotherapy efficacy in colorectal cancer: targeting the FGR-AKT-SP1-DKK1 axis with DCC-2036 (Rebastinib).

Xiguang Chen, Qiting Zeng, Liyang Yin, Bingru Yan, Chen Wu, Jianbo Feng, Ying Wu, Jun He, Wenjun Ding, Jing Zhong and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. DCC-2036 induces repolarization of TAMs to M1 type and enhances CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  4. Article
  5. SMAGS-LASSO: A Novel Feature Selection Method for Sensitivity Maximization in Early Cancer Detection.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiguang Chen *The First Affiliated Hospital, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, PR China.ORCID 0000-0002-6553-8528
Qiting Zeng *The First Affiliated Hospital, Department of Clinical Laboratory Medicine, Hengyang, Hunan, 421001, PR China.
Liyang YinThe First Affiliated Hospital, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, PR China.
Bingru YanCentral Hospital of Hengyang City, Oncology Department, Hengyang, Hunan, 421001, PR China.
Chen WuThe First Affiliated Hospital, Department of Ultrasound Imaging, Hengyang Medical School, University of South China, Hengyang, 421001, China.
Jianbo FengThe First Affiliated Hospital, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, PR China.ORCID 0000-0002-2447-3326
Ying WuThe First Affiliated Hospital, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, PR China.
Jun HeThe Nanhua Affiliated Hospital, Department of Spine Surgery, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Wenjun DingThe First Affiliated Hospital, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, PR China.
Jing ZhongThe First Affiliated Hospital, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, PR China.ORCID 0000-0003-4593-4897
Yingying ShenThe First Affiliated Hospital, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, PR China. shenyingying1113@126.com.
Xuyu ZuThe First Affiliated Hospital, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, PR China. zuxuyu0108@hotmail.com.

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81972487National Natural Science Foundation of China (National Science Foundation of China) 82103171National Natural Science Foundation of China (National Science Foundation of China) 82271506National Natural Science Foundation of China (National Science Foundation of China) 82473223
6 · The paper itself

Abstract

This research demonstrates that DCC-2036 (Rebastinib), a potent third-generation tyrosine kinase inhibitor (TKI), effectively suppresses tumor growth in colorectal cancer (CRC) models with functional immune systems. The findings underscore the capacity of DCC-2036 to enhance both the activation and cytotoxic functionality of CD8

Indexed as

Colorectal NeoplasmsImmunotherapyIntercellular Signaling Peptides and ProteinsProto-Oncogene Proteins c-aktAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansMiceSignal TransductionDKK1 protein, humanIntercellular Signaling Peptides and ProteinsProto-Oncogene Proteins c-akt

Identifiers

PMID39788945
PMCPMC11718245

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.